Sanders Morris Harris LLC Purchases 314,950 Shares of Sera Prognostics, Inc. $SERA

Sanders Morris Harris LLC acquired a new stake in shares of Sera Prognostics, Inc. (NASDAQ:SERA) during the third quarter, HoldingsChannel reports. The fund acquired 314,950 shares of the company’s stock, valued at approximately $642,000.

Other institutional investors have also added to or reduced their stakes in the company. Arkadios Wealth Advisors purchased a new stake in shares of Sera Prognostics in the 1st quarter worth about $25,000. Segall Bryant & Hamill LLC bought a new stake in shares of Sera Prognostics during the 1st quarter valued at about $193,000. Finally, AWM Investment Company Inc. bought a new stake in shares of Sera Prognostics during the 2nd quarter valued at about $377,000. 54.64% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut shares of Sera Prognostics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $5.50.

Sera Prognostics Stock Performance

Shares of NASDAQ:SERA opened at $2.07 on Thursday. Sera Prognostics, Inc. has a 52-week low of $1.56 and a 52-week high of $3.95. The firm has a market capitalization of $81.66 million, a P/E ratio of -3.09 and a beta of 1.06. The stock has a 50 day moving average price of $2.05 and a 200-day moving average price of $2.02.

Sera Prognostics (NASDAQ:SERA) last released its earnings results on Wednesday, August 12th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.03). Sera Prognostics had a negative net margin of 47,475.72% and a negative return on equity of 46.71%. The firm had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.07 million. On average, equities analysts forecast that Sera Prognostics, Inc. will post -0.62 EPS for the current fiscal year.

Insider Transactions at Sera Prognostics

In other Sera Prognostics news, CEO Zhenya Lindgardt sold 20,139 shares of the stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $2.00, for a total value of $40,278.00. Following the completion of the transaction, the chief executive officer owned 844,870 shares in the company, valued at approximately $1,689,740. This represents a 2.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 39,661 shares of company stock valued at $79,563 in the last ninety days. 11.30% of the stock is currently owned by corporate insiders.

Sera Prognostics Profile

Sera Prognostics, Inc is a women’s health diagnostics company focused on improving pregnancy outcomes through biomarker-based testing. The company develops and commercializes blood tests designed to identify women at elevated risk for pregnancy complications, particularly spontaneous preterm birth.

Its lead product, the PreTRM Test, is a blood-based test that analyzes proteins associated with pregnancy and provides an individualized risk assessment for spontaneous preterm birth in singleton pregnancies.